India’s cancer burden is rising, but access to advanced treatments has long been limited by cost and availability. Immuneel is building indigenous CAR-T cell therapy in India, bringing a globally validated treatment for blood cancers to patients at a fraction of the cost seen in the US and Europe. The company has already secured regulatory approval and commercial launch for its first therapy, with a growing hospital network and additional indications progressing through clinical trials. Immuneel is helping position India to build the infrastructure and innovation needed to meet its cancer care needs as the country ages. Read our thesis here.